Año 2021 / Volumen 28 / Número 3

Editorial

Dolor neuropático: un reto constante
Neuropathic pain: a constant challenge

Rev. Soc. Esp. Dolor. 2021; 28(2): 111-114 / DOI: 10.20986/resed.2021.3938/2021

Javier Vidal






Artículo Completo

Bibliografía

1. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain. 2006;122(3):289-94. DOI: 10.1016/j.pain.2006.02.002.
2. Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Neuropathic pain in the community: more under-treated than refractory? Pain. 2013;154(5):690-9. DOI: 10.1016/j.pain.2012.12.022.
3. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654-62. DOI: 10.1016/j.pain.2013.11.013.
4. Jay GW, Barkin RL. Neuropathic pain: etiology, pathophysiology, mechanisms, and evaluations. Dis Mon. 2014;60(1):6-47. DOI: 10.1016/j.disamonth.2013.12.001.
5. Montero A, Samper D, Vidal J, Rodríguez MJ, Jiménez L. Study to evaluate the profile of patients attending pain units in Spanish hospitals for the first time (PANDHORA study). Pain Manag. 2012;2(3):209-17. DOI: 10.2217/pmt.12.19.
6. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-7. DOI: 10.1016/j.pain.2007.08.013.
7. Gálvez R, Marsal C, Vidal J, Ruiz M, Rejas J. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain. 2007;11(3):244-55. DOI: 10.1016/j.ejpain.2006.02.002.
8. Perez C, Galvez R, Huelbes S, Insausti J, Bouhassira D, Diaz S, Rejas J. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007;5:66. DOI: 10.1186/1477-7525-5-66.
9. Pérez C, Gálvez R, Insausti J, Bennett M, Ruiz M, Rejas J; Group for the study of Spanish validation of LANSS. Adaptación lingüística y validación al castellano de la escala LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) para el diagnóstico diferencial del dolor neuropático [Linguistic adaptation and Spanish validation of the LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain]. Med Clin (Barc). 2006;127(13):485-91. DOI: 10.1157/13093266.
10. Patel KV, Amtmann D, Jensen MP, Smith SM, Veasley C, Turk DC. Clinical outcome assessment in clinical trials of chronic pain treatments. Pain Rep. 2021;6(1):e784. DOI: 10.1097/PR9.0000000000000784.
11. Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79(2):231-52. DOI: 10.1016/s0039-6109(05)70381-9.
12. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108(3):248-57. DOI: 10.1016/j.pain.2003.12.024.
13. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638-52. DOI: 10.1016/j.neuron.2012.02.008.
14. Fitzmaurice BC, Rayen ATA. Treatments for neuropathic pain: up-to-date evidence and recommendations. BJA Educ. 2018;18(9):277-83. DOI: 10.1016/j.bjae.2018.06.002.
15. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73. DOI: 10.1016/S1474-4422(14)70251-0.
16. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;2012(7):CD008943. DOI: 10.1002/14651858.CD008943.pub2.
17. Di Stefano G, Di Lionardo A, Di Pietro G, Cruccu G, Truini A. Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis. Pain Res Manag. 2021;2021:6656863. DOI: 10.1155/2021/6656863.
18. Yu X, Liu H, Hamel KA, Morvan MG, Yu S, Leff J, et al. Dorsal root ganglion macrophages contribute to both the initiation and persistence of neuropathic pain. Nat Commun. 2020;11(1):264. DOI: 10.1038/s41467-019-13839-2.

Tablas y Figuras

Tabla I

Figura 1

Artículos relacionados

Instrucciones para citar

Vidal J. Dolor neuropático: un reto constante. Rev Soc Esp Dolor 2021; 28(2): 111-114 / DOI: 1020986/resed20213938/2021


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 3893 veces.
Este artículo ha sido descargado 130 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 26/07/2021

Prepublicado: 26/07/2021

Publicado: 30/07/2021


Compartir

Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:
© 2021 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

      Indexada en: